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Summary- 
Islet transplantation provides an approach to compensate for loss of insulin producing cells in 
patients with type 1 diabetes. However, the intraportal route of transplantation is associated 
with instant inflammatory reactions against the graft and subsequent islet destruction as well. 
While matrix metalloproteases (MMP) 2 and 9 are involved both in remodelling of 
extracellular matrix and leukocyte migration, their influence on the outcome of islet 
transplantation has not been characterized. 
Analysis of MMP-2 and MMP-9 in islet cells by zymography, gelatin dequenching
 
assays, 
and western blot showed that in normal state, islets were expressing less MMP but treatment 
with inflammatory cytokines increased MMP-2 and MMP-9 secretions from them. However, 
islet transplantation in mice liver showed less MMP activity in the transplanted islet and more 
with the recipient liver. We observed comparable MMP-2 mRNA expressions in control and 
transplanted groups of mice, whereas MMP-9 mRNA and protein expression levels increased 
after islet transplantation. Immunostaining for CD11b (Mac-1) expressing leukocytes 
(macrophage, neutrophils) and Ly6G (neutrophils) revealed substantially reduced 
inflammatory cell migration into islet-transplanted liver in MMP-9-knockout (KO) recipients.  
Moreover, gelatinase inhibition resulted in a significant increase in the insulin content of 
transplanted pancreatic islets and reduced macrophage and neutrophil influx as compared to 
the control group.  
These results indicate that increase of MMP-9 expression and activity after islet 
transplantation is directly related to enhanced leukocyte migration and that early islet graft 
survival can be improved by inhibiting MMP-9 (gelatinase B) activity. 
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Zusammenfasung- 
Die Inselzelltransplantation bietet einen Ansatz in der Therapie von Patienten mit Typ 1 
Diabetes, um den Verlust insulinproduzierender Zellen zu kompensieren. Allerdings ist die 
Transplantation auf dem Wege der intraportalen Applizierung mit einer sofortigen 
Entzündungsreaktion gegen das Transplantat und nachfolgend mit einer Zerstörung der 
Inselzellen assoziiert. Obwohl die Matrix-Metalloproteasen (MMP) 2 und 9 sowohl an der 
Umbildung von extrazellulärer Matrix, als auch an der Leukozyten-Migration beteiligt sind, 
wurde ihr Einfluss auf den Ausgang von Inselzelltransplantationen bisher nicht beschrieben. 
Die Untersuchung der MMP-2 und MMP-9 in Inselzellen mittels Zymographie, Gelatine 
Dequenching Assay und Western Blot zeigte zum einen, dass Inselzellen unter 
Normalbedingungen wenig MMP exprimieren, zum anderen aber, dass sie unter Behandlung 
mit entzündungsfördernden Zytokinen mehr MMP-2 und MMP-9 sezernieren. Die gemessene 
MMP-Aktivität war jedoch nach der Transplantation von Inselzellen in die Leber von Mäusen 
in den transplantierten Inseln niedriger und in der Empfängerleber höher. Wir fanden 
vergleichbare Expressionen von MMP-2-mRNA in der Kontrollgruppe und in der Gruppe der 
transplantierten Mäuse, wohingegen die Expressionslevel von MMP-9-mRNA und -Protein in 
Inseltransplantaten höher lagen. Die immunhistologische Färbung von CD11b-(Mac-1-) 
exprimierenden Leukozyten (Makrophagen, Neutrophile) und Ly6G (Neutrophile) offenbarte 
eine erheblich reduzierte Migration von Entzündungszellen in die Leber von MMP-9-
knockout (KO) Empfängertieren, in die die Inseln transplantiert wurden. Zudem führte die 
Hemmung der Gelatinase zu einer signifikanten Zunahme des Insulingehaltes in 
transplantierten Inseln aus dem Pankreas und zu einer Abnahme der Makrophagen- und 
Neutrophileninfiltration im Vergleich zur Kontrollgruppe. 
Diese Ergebnisse deuten darauf hin, dass eine Zunahme der MMP-9-Expression und -
Aktivität nach einer Inselzelltransplantation direkt im Zusammenhang mit einer gesteigerten 
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Leukozytenmigration steht und, dass das frühe Überleben der Transplantate durch die 
Hemmung der MMP-9- (Gelatinase B) Aktivität gefördert werden kann. 
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1. Matrix metalloproteases (MMPs) 
MMP are a family of zinc-dependent endopeptidases composed of more than 20 members. 
They are involved in the turnover of the ECM in several conditions including embryonic 
development, inflammatory cell invasion or wound healing (1-4).  
1.1 History 
Matrix metalloproteinases are essential for any individual cell to interact properly with its 
immediate surroundings and for multicellular organisms to develop and function normally.  
MMPs were for the first time discovered by Gross and Lapiere in 1962, when they observed 
that tadpole tail could degrade gels made of fibrillar collagen (5). They concluded that it is a 
matrix-degrading enzyme and named it Collagenase or MMP-1. 
A family of related enzymes has been identified in all species and collectively called matrix 
metalloproteinases (MMPs) because they degrade components of ECM and they need metal 
ions for catalytic activity. 
It took almost a decade after their discovery, when researchers discovered for the first time 
that MMPs are synthesized as inactive zymogens and they require activation (6), and 
demonstrated that MMPs can be inhibited by their natural endogenous metalloproteinase 
inhibitors called tissue inhibitors of metalloproteinase or TIMPs(7) .  
1.2 Structure  
Based on their structural characteristics they are classified into two types -secreted MMPs and 
membrane-anchored MMPs. MMPs are composed of protein domains (fig 1). Generally they 
have an N terminal signal sequence (which is also known as pre-domain) that directs secretion 
of MMP. The pre-domain is followed by pro-domain that makes the enzyme inactive. Once 
this pro-domain is removed, the MMP gets activated (8). The catalytic domain is adjacent to 
the pro-domain and possesses a zinc-binding site. Most of the MMPs have hemopexin-like 
domains at the C-terminal, which mediate substrate and inhibitor interaction. Catalytic 
domain is separated from hemopexin-like domain by a small hinge region which influences 
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substrate specificity (9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Page-McCaw et al. Nature Reviews Molecular Cell Biology 8, 221–233 (March 2007) 
Fig 1 Structure of MMPs. They are generally secreted in an inactive form by the interaction 
between thiol group of a pro-domain cysteine residue and the zinc molecule of the catalytic 
domain (A). Based on their structure we can divide them into four parts. First class of MMPs 
have the basic structure while the second group of MMPs have 3 fibronectin repeats in their 
catalytic domain. Third class of MMPs are with membrane linkage region and the fourth 
group are with minimal domain structure (B). 
 
Some of the MMPs such as MT-MMPs possess membrane-anchored domain and some of the 
MMPs lack hemopexin-like domain (Figure 1B,1-4). This domain influences TIMP binding, 
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some of the substrate binding and enzymatic activity. For example, MMP-1 needs both ends 
for cleaving collagens whereas hemopexin domain performs local unwinding of its triple-
helical structure and sequential cleavage of each alpha-chain individually (10). MMP-2 and 
MMP-9 also contain a module of three fibronectin-type-2 repeats, which they need for 
binding with their substrate (11). 
1.3 MMPs regulation 
Generally, MMPs are not expressed in healthy tissue but their expression can be observed in 
fetal development, inflammatory reactions and in tissue remodelling (1-4). Regulation of 
MMPs is complex and tightly regulated at different levels such as, at the protein level by their 
endogenous activator and inhibitors, the secretion level, the cell surface localization and their 
own degradation after secretion. Details of regulation pathways are mentioned below. 
1.3.1 Regulation at the transcription level 
MMPs are mostly regulated at the transcription level except MMP-2, which expresses 
constitutively and co-regulates with TIMP-2 and MMP-14. There are several factors such as 
cytokines-interleukins, interferon, TNF and growth factors - FGF, VEGF, TGF, which 
regulate MMP expression in different cell types. Most of the MMP promoters contain cis-
elements which can regulate MMP’s gene expression by trans-activators, for e.g.- AP-1, 
PEA3, Sp-1,B-catenin/Tcf-4 and NF-!B (12). 
There are some other factors such as phorbol esters, integrin-derived signals and cell stress 
that stimulate or suppress MMP’s gene expression (13-15).  
1.3.2 Endogenous inhibition of MMPs 
MMPs can be inhibited by their natural inhibitors, which are known as tissue inhibitors of 
metalloproteases (TIMPs). TIMPs are 20-29 kDa-secreted proteins that inhibit MMPs in 
stoichiometric fashion (16). For example, TIMP-2 binds the hemopexin domain of MMP-9 
less readily compared with MMP-2 (17) and TIMP-2, 3 can inhibit MT1-MMP but TIMP-1 
cannot (18). TIMPs also regulate target genes and are tissue specific.  
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Alpha2-macroglobulin is another major endogenous inhibitor of MMPs (19). It is an abundant 
plasma protein that essentially inhibits MMPs in tissue fluids, whereas TIMPs act on the 
cellular level. Alpha2-macroglobulin/MMP complexes are cleared irreversibly by scavenger 
receptors while TIMPs inhibit MMPs in a reversible manner. 
1.3.3 Regulation at secretion level 
After translation MMPs are constitutively secreted but some of them reside within the 
intracellular compartment. For example MMP-9 is synthesized by neutrophilic granulocytes 
in the bone marrow and stored in tertiary granules. Once granulocyte are activated they 
secrete these MMPs (20). Plasmin and thrombin activate MMP-12 secretion from 
macrophages but without inducing transcription of MMP-12 (21). 
1.3.4 Regulation from inactive form to active form 
MMPs are generally secreted in the inactive form and get activated when cysteine-to-zinc 
switch is opened by normal proteolytic removal of the propeptide domain (22). Some MMPs 
such as MMP-11, MMP-27 and MT-MMPs contain furin-like-enzyme motif, which can 
become active by intracellular subtilisin type intracellular serine proteases before they reach 
the cell surface (23). The extracellular activation of most MMPs can be initiated by other 
already activated MMPs or by several serine proteinases that can cleave peptide bonds within 
MMP pro-domains (24)  
1.3.4 Regulation of pericellular proteolytic activity 
MMPs can also be regulated in pericellular space by regulating membrane bound MT-MMPs 
expression by binding of MMPs to cell surface receptor such as MMP-2 binds with alpha v 
beta 3-integrin (25) and MMP-9 to CD44 (26). Presence of cell surface receptors for enzymes 
such as uPA/plasmin, thrombin and elastase (27-29) also influence MMP functions as 
catalytic processes enhance MMP activity in the pericellular space, limit the inhibitors of 
MMPs and thereby increase the probability of proteolysis of MMP targets. 
1.3.5 MMPs catabolism 
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MMP degradation or clearance is another way of inactivating them. It has been shown that 
alpha2-macroglobulin forms a complex with MMP and by endocytosis permanently clears 
this complex (19). Thrombospondin (TSP) has also been implicated in the clearance of 
MMPs. The low-density lipoprotein receptor-related protein (LRP) mediates the endocytic 
clearance of various proteinases and proteinase inhibitor complexes, including 
thrombospondin (TSP)-dependent endocytosis of MMP-2 (30). 
 1.4 Possible mode of action 
Matrix metalloproteases can degrade not only extracellular matrix but they also provide 
structural support to the cells. In addition they cleave several cell surface receptors and 
cellular junctions and thereby change signalling pathways and cell-cell interactions.  
 
 
Fig 2 Possible mode of action. MMPs can influence a lot of cellular functions such as- 
degradation of ECM, cell migration, cleavage of cell surface receptor, cleavage of cell-cell 
adhesion and removal of ECM binding protein or growth factors. 
 
They release signalling molecules and growth factors from ECM and influence inflammatory 
reactions and cell migration (Fig 2). Some of their main modes of action (Fig 2) are shown 
below. 
1.4.1 Remodelling of extracellular matrix (ECM) 
M.D. Sternlicht and Z.Werb, Annu. Rev. Cell Dev. Biol. 2001. 17:463–516 
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ECM is a complex structural entity, which provides support for cells. The ECM is composed 
of three major insoluble structural classes of molecules: collagens, elastins, and specialized 
proteins such as fibrillin, fibronectin, laminin and proteoglycans. MMPs can degrade different 
components of the ECM, which are shown in Fig 3. 
ECM not only provides cell support but is also a site of embedded growth factors and 
cytokines. It releases cryptic sites that are mostly made by ECM degradation, for instance 
MMPs cleave native fibrillar collagen and expose cryptic RGD sites that can be ligated by 
alpha v-beta 3 integrin, and this interaction promotes the expansion of tumor cells (31). 
Another component of basement membranes, laminin-5, has a cryptic site, which is the "2 
chain of laminin that induces epithelial cell migration (32). MMP-2 and MMP-9 expose a 
cryptic epitope within collagen IV that supports endothelial proliferation (33, 34). 
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Pathology International 2010; 60: 477–496 
Fig 3 MMPs and their substrates. 
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1.4.2 MMPs regulate inflammatory reaction 
Inflammation is always characterized by several steps such as recruitment of leukocytes, 
activation of leukocytes, plasma derived inflammatory mediators and increase in 
inflammatory cytokine secretion. Though inflammation is necessary for host defence, it is 
harmful if unregulated or excessive. Increase in MMPs expression has been associated with 
almost every inflammatory disease. MMPs regulate several inflammatory mediators such as 
cytokines and chemokines and establish chemokine gradients in inflamed tissues that regulate 
migration of leukocytes to sites of inflammation (35-37). 
Leukocytes release MMPs and extravagate by cell-cell junction, by cleaving components of 
the basement membrane or interstitial matrix. MMPs are also known to influence leukocyte 
migration by increasing chemokine activation, for instance MMP-9 can activate chemokines 
CXCL5, CXCL8, CXCL6 (38) and cytokine TGF-beta (39). Similarly MMP-2, MMP-9 and 
MMP-3 activate IL1-beta precursor and MMP-3 can degrade active IL1-beta (35). During 
inflammation neutrophils release MMP-8 and MMP-9 which degrades type 1 collagen and 
generates an acetylated tripeptide mimicking the chemotactic effects of chemokine ligand 
8(CXCL8) and enhances neutrophil recruitment to site of inflammation (40). 
1.4.3 Cleavage of cell surface molecules 
MMPs can release cell surface molecules and thereby influence a lot of signalling pathways. 
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and 
participates in tumour cell resistance to natural killer cell-mediated cytotoxicity (41). MMP-3 
cleaves soluble L-selectin from leukocytes and releases active heparin binding EGF-like 
growth factor from cell surface (42, 43). MMP-7 cleaves the NR1 subunit of the N-methyl-d-
aspartate (NMDA) receptor, which is associated with NMDA stimulated calcium flux in 
neurons. (44). 
2. Type 1 diabetes and islet transplantation 
Type 1 diabetes is defined as an autoimmune disease that results in the permanent destruction 
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of insulin producing beta cells of the pancreas. In this disease the immune system self-
destroys beta cells in the islets of Langerhans of the pancreas and eliminates insulin 
production. Even though it can occur at any age usually it starts in people younger than 30 
and is therefore also known as juvenile onset diabetes (45). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cnop M et al, Diabetes 54 Suppl 2:S97-107, 2005 
Fig 4 Type 1 diabetes. In type I diabetes immune cells destroy beta cells of pancreas and 
thereby patients need to inject insulin. 
 
2.1 Treatment of T1D  
Type 1 diabetes is associated with metabolic abnormalities, which can lead to several chronic 
and degenerative complications in patients, including retinopathy, nephropathy, neuropathy, 
atherosclerosis and lipid disorders. It can be treated by either injecting exogenous insulin or 
by performing whole pancreas or islet transplantation. Recent studies have shown that 
transplantation is a better approach than exogenous insulin therapy as transplantation can not 
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only restore insulin production, but also reduce diabetic complications more effectively. On 
the whole, organ transplantation is associated with major surgery and the risk of surgical 
complications, islet cell transplantation is less critical and can be obtained by minor surgery 
(45). 
2.2 Islet cell transplantation 
Islet cell transplantation provides an approach used in patients with type 1 diabetes to 
compensate for loss of insulin producing cells. In this therapeutic procedure, islet cells are 
injected into the liver via the portal vein, where they take up residence and begin to produce 
insulin (45, 46).  
  
 
 
 
 
 
 
 
 
 
    Adapted Juan J. Blondet et al, Surg Clin N Am 87 (2007) 1477–1501 
Fig 5 Islet transplantation process. It includes islet isolation from donor pancreas and then 
isolation of islet followed by injection of islet in recipient liver.  
 
As in normal conditions insulin from pancreatic beta cells is secreted directly into portal vein 
system and degraded in the liver, it was hypothesised that the islet transplantation in liver can 
provide a similar physiological situation. Later several islet transplantation experiments 
confirmed this hypothesis. This method has another advantage of having minimal invasion 
procedure (46). 
Pancreas 
 Portal vein 
Islet isolation 
Donor Human  
Recipient Human  
Pancreas 
 
Islet in Pancreas 
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2.3 History of islet cell transplantation 
First time in 1892 Minkowsky reported that removal of pancreas was associated with diabetes 
in dog and in 1893 English surgeon Watson Williams transplanted sheep pancreatic fragments 
into a 15 year old boy with end stage type 1 diabetes however the boy died after few days due 
to immune rejection of islets which at the time people were not aware of (45). 
Paul E. Lacy at Washington University proposed that islet cell transplantation may be a better 
option than insulin treatment as it can not only cure diabetes but can also prevent chronic 
complications of diabetes. In 1972, he successfully reversed diabetes by transplanting 
pancreatic islets in a rodent model sytem (47). In 1986 an automated method of islet isolation 
was resolved and this yielded a sufficient number of islets. In 1990, for the first time 
Pittsburgh’s group performed successful human islet allograft which was achieved by using a 
steroid free immunosuppressor with insulin independence up to 5 years (48). In 1996, by 
including the use of endotoxin-free reagents and improved peritransplant recipient treatment, 
the Giessen group headed by R.G. Bretzel and B. Hering were able to achieve a 100% initial 
graft function and a 40% insulin independence after 1 year following transplantation (45). In 
2000 Shapiro and colleagues introduced one of the most sucessful protocols in transplantation 
history, which was named Edmonton protocol (49). In this protocol rapamycin was used as an 
immunosuppressor. From this time more then 100 transplantations have been carried out in 
North America and Europe by using Edmonton protocol with some small changes and insulin 
independence was achieved  in almost 80% patients. 
2.4 Factors influencing graft 
Though islet cell transplantation provides a hope for type 1 diabetes patients, still the rate of 
success of isolated islet transplantation is limited due to inflammatory, apoptotic and 
coagulation processes that occur in the hepatic environment and these appear to be 
responsible for the failure of islet transplantation (50-53). It is estimated that almost 50% islet 
mass damage is experienced immediately after islet transplantation. Factors that are playing 
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an important role in early islet loss are as follows: 
2.4.1 Hypoxia 
Hypoxia is a pathological condition in which the tissue has unduly low oxygen supply. 
Pancreatic islets are richly vascularized in the normal state. Arterial blood flow in the 
pancreas is quite high, 40 mmHg in comparison to portal venous blood 10-15 mmHg, and this 
creates a hypoxic situation in islet vicinity after transplantation to liver (54). 
It has been shown that hypoxia is an important factor, which is affecting islet cell 
transplantation in liver by inducing apoptosis in beta cells after transplantation (55). Hypoxia 
can also reduce NF-!B activation and thereby can inhibit transcription of anti-apoptotic genes 
(55). 
2.4.2 Instant blood mediated inflammatory reaction (IBMIR) and innate immune system 
Islet cell transplantation is also associated with instant blood mediated inflammatory reaction 
(IBMIR), which is occurring when islets are coming in direct contact with blood after 
transplantation (56). This blood coagulation process in the islet surrounding is starting from 
tissue factors (CD142, exposed in islets disrupted from endothelial cells). Tissue factor 
generates thrombin and promotes activation of the complement system (56; 57). Immune cells 
migrate from the blood stream to the liver and into the direction of the transplanted islets (50). 
Inhibition of thrombin activity or its interference with the tissue factor prolongs the function 
of intraportal islet allografts (58; 59). 
It has been shown that even in syngenic islet transplantation into non-autoimmune diabetic 
mice there is almost 60% of islet loss within three days of transplantation due to necrosis and 
apoptosis (60). A key role of macrophages (CD11b positive cells) and their inflammatory 
cytokines was shown in islet survival and their depletion was observed, effectively delaying 
xenogenic islet rejection (61; 62).  
Increased inflammatory cytokine (IL1, IFN-", IL-6) and NO level was observed within few 
hours of transplantation and it was concluded, that although cells from innate immune system 
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(including Kupffer cell) and hepatocytes are potential sources of these factors (53), neutrophil 
granulocytes were also playing the most important role in early islet graft loss (50). It was 
also reported that CD11bGR1 positive cells (neutrophil) are instrumental in early graft loss by 
increasing local inflammatory cytokine production (51). Not only cells from innate immune 
system, but from adaptive system such as T-lymphocytes are accountable for allograft 
malfunction (63).  
2.4.3 Other Factors 
There are several other factors that can induce later islet graft loss such as islet amlyoid 
formation and lipotoxicity. It has been described that islet amlyoid formation occurs in 
isolated human cultured islets (64) and a recent study indicates that amyloid forms after 
clinical islet transplantation. Lipogenesis is the process where acetyl-CoA is converted to fats 
and it has been shown that after islet transplantation insulin induces lipogenesis in nearby 
hepatocytes. Blocking of lipogenesis improved islet graft survival (65). 
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3. MMPs in diabetes and islet transplantation 
Cell extracellular matrix (ECM) interactions have been shown to influence islet integrity, 
proliferation, differentiation and insulin secretion (66-68). MMPs were for the first time 
discovered in islet by Barro et al in 1997 when he found that islets are capable of secreting 
gelatinase.  
Cells from innate immune system such as neutrophils and macrophages express and secrete 
gelatinases (69). Previous studies have shown that such cells contribute to the first line of 
rejection following islet transplantation (50; 51). Moreover, elevation of MMP-9 plasma 
levels was observed in diabetic patients (70; 71), while in mice with acute pancreatitis, trypsin 
induced the activation of MMP-2 and 9. When activated by endogeneous trypsin, MMP-9 was 
diabetogenic, as it cleaved secreted insulin (71; 72). Tissue inhibitor of MMP-1 (TIMP1) 
protects against apoptosis and restores glucose-stimulated insulin release of islets in the 
presence of cytokines (73). Also, inhibition of pancreatic MMP-9 activity suppressed 
leukocyte migration and inflammation in type 1 diabetes (74). Basement membrane-
degrading gelatinases, such as MMP-9, play an important role in immune-mediated tissue 
destruction (2,3). Thus, MMP-9 may serve as a candidate target for therapeutic intervention, 
as gelatinase activity could change the ECM composition of transplanted islets and, at the 
same time, promote leukocyte migration into the graft.  
The present study was therefore undertaken to investigate the role of gelatinases in islet 
transplantation. 
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4. Aims of the study 
Intraportal islet transplantation is characterized by an instant inflammatory reaction against 
the graft with subsequent islet destruction. It is known that gelatinases (matrix 
metalloproteases
 
2 and 9) are involved in both inflammation and leukocyte migration. 
Therefore, we investigated the influence of gelatinase on the outcome of islet transplantation.  
The general aim of the present work was to investigate the role of gelatinases in islet cell 
transplantation into liver tissue and to provide measures for the protection of transplanted 
islets against the infiltration of immune cells. 
Following specific aims were addressed to achieve our goal- 
1- Gelatinase secretion from islets after isolation with and without cytokines treatment. 
2- Association of gelatinase activity to islet transplanted liver. 
3- Immune cell migration in islet transplanted liver 
4- Effect of gelatinase inhibition on islet graft survival and immune cell migration. 
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1 Materials 
1.1 Chemicals 
Product         Manufacturer 
Acetic acid         Roth 
Agarose(LM-MP)       Sigma  
Agarose         Invitrogen 
Ammonium persulfate (APS)      Bio-Rad 
Bovine serum albumin (BSA)      Sigma 
Calcium chloride (CaCl2)       Sigma 
Calcein-AM solution       Sigma 
Collagenase D       Roche 
DNAse I        Roche 
DQ-Gelatin        Invitrogen 
DMEM 41966 Medium       Invitrogen Gibro 
Dimethyl sulfoxide (DMSO)       Fluka 
ECL Western Blotting Substrate      Thermo Scientific Pierce 
EDTA         Fluka 
Ethanol         Merck 
Ethylendiaminetetraacetic acid (EDTA)     Fluka 
Fetal calf serum (FCS)       Bio West 
Formaldehyde        Roth 
Glucose         Sigma 
Glycine         Roth 
Gelatine         Sigma 
HEPES         Sigma 
Hoechst 33342        Sigma 
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Hydrochloric acid (HCl)       Merck 
Isopropanol         Merck 
Magnesium chloride (MgCl2)      Merck 
Magnesium sulfate (MgSO4)      Merck 
!-Mercaptoethanol        Fluka 
Methanol         Merck 
Percoll         GE-Healthcare 
Potassium chloride (KCl)       Fluka 
RPMI-1640        Gibco 
Tissue-Tek O.C.T. Compound      Sakura 
Skim milk powder        Merck 
Sodium azide (NaN3)       Fluka 
Sodium chloride (NaCl)       Roth 
Sodium dodecyl sulfate (SDS)      Bio-Rad 
Sodium dihydrogen phophate (NaH2PO4)     Acros organics 
di-Sodium hydrogen phosphate (Na2HPO4)    Merck 
Sodium hydroxide (NaOH)       Fluka 
Sodium orthovanadate (Na3VO4)      Sigma 
N,N,N',N'-Tetra-methyl-ethylenediamine (TEMED)   Bio-Rad 
Thymidine         Sigma 
Tris-base         Acros organics 
Triton X-100         Sigma 
Trypsin/EDTA        Invitrogen Gibro 
Tween 20         Merck 
Zink Chloride        Sigma 
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1.2 List of antibodies-  
Primary Antibody     Dilution    Company 
Guinea Pig Anti-insulin, polyclonal   1:500 (IF)    DAKO 
Rat Anti-Mouse Ly-6G , monoclonal 1:150 (IF,FACS)   eBioscience 
Rat Anti-Mouse CD11b   1:100 (IF)   Immunotool 
Rat anti Mouse CD11b (PE)   1:100(FACS)   BD-Pharmingen 
Rat anti Mouse GpIIb/IIIa (FITC)  1:100(IF)   BD-Pharmingen 
Rat anti-Mouse F4/80    1:100(IF)   AbD Serotec  
MMP-2     1:1000(WB)   Calbiochem 
MMP-9     1:1000(WB)   Millipore 
Rat anti Mouse CD147    1:150 (IF)    Abcam 
 
Secondary antibody     Dilution    Company 
Rhod Red-X-APure Donkey Anti-Guinea Pig  1:400 (IF)  Jackson ImmunoResearch 
Rhod Red-X-APure Donkey Anti Rat   1:400 (IF)  Jackson ImmunoResearch 
FITC-APure Donkey Anti-Guinea Pig   1:400 (IF)  Jackson ImmunoResearch 
FITC-APure Donkey Anti Rat    1:400 (IF)  Jackson ImmunoResearch 
 
1.3 Kits- 
 Kits          Company 
 
BCA Protein Assay Kit       Thermo Scientific Pierce 
Porcine insulin ELISA kit       DRG Instruments 
SuperScript® III Reverse       Transcriptase Invitrogen 
RNeasy Mini         Qiagen 
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1.4 Primers 
Primers for Murine       Product Size 
MMP-2 
Forward Primer 5´-AGATCTTCTTCTTCAAGGACCGGTT-3´ 
Reverse Primer 5´-GGCTGGTCAGTGGCTTGGGGTA-3´   225 bp. 
MMP-9 
Forward Primer 5´-GTTTTTGATGCTATTGCTGAGATCCA-3´ 
Reverse Primer 5´-CCCACATTTGACGTCC AGAGAAGAA-3´   208 bp. 
GAPDH 
Forward Primer–5´-GGAGCGAGACCCCACT AACAT-3´ 
Reverse Primer- 5´-GC GGAGATGATGACC CTTTT-3´     135 bp. 
 
1.5 Recombinant Cytokines 
Cytokines        Company 
IL1-beta        Calbiochem 
TNF-alpha        R&D System 
 
1.6 Instruments and Software 
 Instruments      Company 
FACSCalibur      Becton Dickinson 
Cell Quest software     Becton Dickinson 
Fluorescent Microscope    Leica DMLB 
Gel Doc      Vilber Lourmat 
Bio 1D      Vilber Lourmat 
Elite Glucometer      Bayer 
Fluorescence Plate Reader    Berthold Technologies-Mithras LB940 
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ELISA Reader     DRG Instruments 
Statistic Analysis      GraphPad prism 
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2. Methods 
2.1 Islets isolation and culture 
2.1.1 Mouse islets isolation  
Pancreatic islets were isolated after giving anaesthesia to mice. Pancreas was distended with 
Hanks balanced salt solution (HBSS) containing collagenase (2mg/ml) via the main bile duct. 
Pancreas was surgically removed and the donor was sacrificed. Digestion was performed at 
37°C for 10 minutes in water bath with gentle shaking and terminated by ice cold HBSS. The 
resultant cell suspension of cells was centrifuged at 1000 rpm for 1 min followed by two 
times washing with HBSS. Islets were handpicked under stereomicroscope. Islets were 
cultured in Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10%fetal calf 
serum, penicillin (100 U/ml), and streptomycin (100"g/ml).  
2.1.2 Pig islets isolation 
Pig islets were isolated using previously described techniques of collagenase digestion and 
Ficoll purification (75). Briefly, islets from a single pig pancreas were isolated after vascular 
flush with University of Wisconsin solution (Du Pont Critical Care, Waukegan, USA). The 
quality of islet isolation was evaluated by trypan blue exclusion, dithizone staining and 
glucose-stimulated insulin secretion to check viability, purity and function. Animal research 
was approved by Regional Commission Giessen (Germany) under the code number GI20/11-
Nr.15/2006. Animal husbandry was performed according to the German Animal Welfare Law 
as published in the latest version under http://bundesrecht.juris.de/tierschg. 
Pig islets were cultured at non-CO2 air in CMRL 1066 (PAA, Pasching, Austria) 
supplemented with 25 mM HEPES, 20% heat-inactivated pig serum, 100 U/ml penicillin 
(Biochrom, Berlin, Germany), 100 "g/ml streptomycin and 2 mg/ml glucose. 
2.2 Gelatin Zymography 
2.2.1 Measurement of protein concentration 
Cells were cultured in serum free medium. Culture conditioned medium was collected and 
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protein concentration was measured by Bicinchoninic acid assay (BCA) kits (Pierce). 
Whenever islet-transplanted liver tissue was used then it were homogenised by using lysis 
buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% SDS, and 0.1% Na-deoxycholate) and 
were centrifuged for 20 min at 4°C at 9000 g. Protein concentration was measured by BCA 
protein assay (Pierce) for all samples. BCA assay was first time discovered by Paul K Smith 
at the Pierce Chemical Company. In this assay peptide bonds in protein reduce Cu2+ ions 
form cupric sulfate to Cu1+ and the amount of Cu2+ reduced is proportional to the amount of 
protein. Later two molecule of Bicinchoninic acid chelate with each Cu1+ ion and form a 
purple colourd product that absorbs light at 562 nm. The amount of protein present in solution 
can be quantified by comparing with known concentration of protein solution such as BSA. 
2.2.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS – PAGE) and 
zymograpy 
Equivalent amount of protein volume was adjusted to equal amount with 1x SDS-sample 
buffer without EDTA and B-mercaptoethanol. Samples were then electrophoresed on SDS-
PAGE containing substrate gelatine (0.2%) that can be readily cleaved by MMPs. The 
following solutions were used- 
 Seperation gel (8%)      Stacking gel(5%) 
Lower Buffer    3.75 ml    Upper Buffer  2.5ml 
AA(30%)   4ml    AA   1.65 
H2O    5.8 ml     H2O   5.7ml 
APS(10%)   100µl    APS   100µl 
TEMED   10µl    TEMED  10µl 
Gelatine   0.2% 
Lower Buffer-   1.5 M Tris/HCL pH-8.8 
    0.4% SDS    
Upper Buffer-   1 M Tris/HCL pH-6.8 
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    0.4% SDS 
5x SDS running buffer- 1.250M Glycine 
    0.125 M Tris 
    1% SDS 
 
After electrophoretic separation of proteins, gels were washed thrice, 15 min each, in 
2.5%triton X-100. Gels were then treated with incubation buffer for 2days at 37°C and then 
stained with Coomassie Brilliant Blue R-250.  
Incubation Buffer- 50mM Tris-HCL, pH 7.6,  
   0.1% NaN3,  
   1% Triton X-100, 
    10 mM CaCl2  
   1 M ZnCl2 
After destining the gel clear bands indicated gelatinase activity. Gels incubated with 
incubation buffer containing 5 mM EDTA were used as negative control. 
2.3 Western blot 
For detection of MMP-2, serum-free conditioned medium was collected from islets with and 
without treatment. Equivalent amount of protein was separated by SDS –PAGE (as described 
above but without gelatin) and transferred to PVDF membrane at 4° C. Membranes were 
blocked by incubating with 5% skim milk powder (Fluka). Membranes were washed with 
TBST (0.1% Tween 20) and incubated with primary antibody anti-MMP-2 (Calbiochem) 
overnight at 4°C. Subsequently, membranes were washed thrice with TBST (0.1% Tween) at 
room temperature and incubated with polyclonal rabbit anti-mouse HRP conjugated antibody 
for one hour. Protein expression was detected by enhanced chemiluminescence system 
(Pierce). 
Transfer buffer   50 mM Tris 
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40 mM Glycine 
0.04% (w/v) SDS 
20% Methanol 
 
10 x TBS    250 mM Tris pH 7.4 
1.5 M NaCl 
50 mM KCl 
 
2.4 Islet transplantation 
Diabetes was induced in C57Bl/6 recipients (12 weeks old, male) by a single injection of 200 
mg/kg streptozotocin (Sigma, Munich, Germany) intraperitoneally and blood glucose levels 
were monitored by glucometer Elite (Bayer, Leverkusen, Germany). Mice with a non-fasting 
blood glucose concentration of more than 16.7 mmol/L for two consecutive days were 
selected for transplantation. Recipients were anesthesized with avertine and maintained with 
isoflurane. Two thousand islet equivalent (IEQ) porcine islets washed with PBS were 
transplanted into the liver via the portal vein of mice with a 27-gauge needle using a 
previously described method with modifications (75). MMP-9 KO and respective control 
mice (6-7 weeks old) were a gift from Eva Korpos, (Westfälische Wilhelms-Universität, 
Münster, Germany). They were originally generated at the University of Leuven, Belgium 
(76) and backcrossed with C57Bl/6 mice for more then 10 generations. Mice were 
characterized for absence or presence of MMP-9 by using both RT-PCR and gel gelatin 
zymography. Similar transplantation method was used for transplanting pig islet in MMP-9 
KO mice.  
2.5 RT-PCR 
Following islet transplantation animals were killed after 4 h and total RNA was prepared from 
liver by using TRIzol reagent (Invitrogen, Darmstadt, Germany) according to the 
manufacturer's instructions to analyze m-RNA expression of MMP-2 and MMP-9. Reverse 
transcription was performed for 15 min at 70°C followed by 2 min incubation at 95°C for 
denaturation. Amplification started by 15s at 94°C, 20 s at 60°C, and 10s at 72°C for 39 
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cycles. RT-PCR products were loaded on 2% agarose gels and analyzed after staining with 
syber green (Invitrogen) using imaging system BIO 1D (Vilber Lourmat, Eberhardzell, 
Germany). 
2.6 In situ gelatin zymography with immunohistochemistry  
Cryostat sections (7 "m) of pancreas and islet-transplanted liver were fixed in precooled 
acetone for 10 min. The sections were washed thrice with PBS. Following blocking with 3% 
donkey serum, sections were incubated with polyclonal guinea pig anti-swine insulin primary 
antibody (Dako, Glostrup, Denmark) for 2 h. After using a donkey anti-guinea pig secondary 
antibody (RhodRedx, Jackson ImmunoResearch, Hamburg, Germany), in situ zymography 
was performed. DQ gelatin (10%, Invitrogen) that was dissolved in 1% agarose LM-MP 
(Roche, Grenzach, Germany) containing 10 "M ZnCl2, 1 mM CaCl2, 1 "l DAPI was put on 
top of the cover slip to cover each tissue. Slides were kept in a moist chamber at 37°C and at 
time 0 (immediately after placing sections on the slides) as well as after 1 h, sections were 
viewed in a fluorescent microscope (Leica DMLB, Germany) and processed in Leica 
Application Suite. Gelatin gel with captopril (10 mM, Sigma) was taken as negative control. 
The presence of autofluorescence was excluded by incubating sections in agarose-containing 
medium without DQ-gelatin.The presence of autofluorescence was tested by incubating 
sections in agarose-containing medium without DQ-gelatin 
2.7 Immunohistochemistry 
Pig islets were transplanted into mice liver and after 4 h; islet-transplanted livers were 
embedded in TissueTek OCT compound and snap-frozen in liquid nitrogen. Frozen sections 
(7 "m) were prepared, using a cryostat and were stored at -20°C until used for staining. 
Sections were fixed in 10% acetone at -20°C and blocked with 10% donkey serum. After 
washing with PBS the sections were incubated overnight at 4°C with rat anti-mouse Ly-6G 
(Gr1, Clone RB6-8C5, eBioscience, Frankfurt, Germany) and rat anti-mouse CD11b (Mac-1, 
ImmunoTools, Friesoythe, Germany) in a humidifier. The sections were washed in PBS and 
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incubated with secondary antibodies FITC-donkey anti-rat for CD11b and Ly-6G (all from 
Jackson ImmunoResearch) for 1 h at 22°C. Sections were washed again with PBS and 
counterstained with DAPI being inspected under the fluorescent microscope. The same 
method was used for MMP-9 staining in control and transplanted liver whereby rabbit anti-
MMP-9 polyclonal antibody (Millipore) was used as primary and RhodRedx-donkey anti-
rabbit as secondary antibody. For insulin staining guinea pig anti-insulin primary antibody 
and FITC-donkey anti-guinea pig (Jackson ImmunoResearch) secondary antibody was used. 
In addition, some sections were incubated with rat anti-mouse F4/80 (AbD Serotec, 
Dusseldorf, Germany) primary antibody and RhodRedx -donkey anti-rat secondary antibody. 
F4/80 positive cells were counted (200x magnification) in fields of liver sections without islet 
or in the proximity of transplanted islets at different time points. 
2.8 Liver leukocyte preparation 
Islet-transplanted livers were perfused through the vena cava with 20 ml of PBS, followed by 
the removal of the gall bladder and careful excision of the liver from the abdomen. Isolation 
of single cells by mechanical disruption in RPMI (RPMI without phenol red containing 10% 
FCS, 25 mM HEPES) with surgical scissor was performed. This preparation was dissolved in 
RPMI containing collagenase and DNase (RPMI without phenol red containing 10% FCS, 25 
mM HEPES, 0.5 mg/ml collagenase D, 0.025 mg/ml DNaseI) and kept for 45 min at 37°C 
with shaking (1 cycle/s). The reaction was stopped by addition of 20 mM EDTA. After 
passing the content through 100 µm cell strainer, RPMI containing 5% FCS was added, 
followed by centrifugation at 1250 rpm for 15 min at 4°C. The cell pellet was mixed with 
40% Percoll and then poured on top of 70% Percoll. After centrifugation at 2000 rpm for 20 
min at 20°C leukocyte were removed from the interphase of the gradient, washed with RPMI 
and used for analysis by FACSCalibur (Becton Dickinson, Heidelberg, Germany). 
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Fig 1 Liver leukocyte preparation. Liver single cells was mixed with 40% percoll and poured 
on top of 70% Percoll (A). After centrifugation without breaks leukocyte cells were removed 
from interphase of gradient (B). 
 
2.9 Antibodies and flow cytometric analysis 
40% Percoll with liver single cells 
70% Percoll 
A 
Leukocytes 
Hepatocytes 
B 
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one million cells were suspended in PBS containing 0.3% BSA and 0.1% sodium azide. For 
inhibiting non-specific binding of antibodies, Fc-receptors were blocked by pre-incubating 
cells with monoclonal antibody directed against the FcR III/II CD16/CD32 (BD Biosciences). 
Cells were incubated with 1 "g/ 10
6 
cells of the CD11b antibody (PE-conjugated anti-CD11b, 
BD-bioscience) and Gr1 (FITC- conjugated anti Gr1, BD-bioscience) for 45 min at 4°C and 
washed twice. They were analyzed by using Cell Quest software for FACSCalibur (Becton 
Dickinson). 
3.0 Peritoneal macrophage isolation 
Four percent brewer’s thioglycollate medium (Becton Dickinson, Heidelberg, Germany) was 
injected into the peritoneal cavity of each mouse. Peritoneal fluid was obtained 72h after 
injection by flushing the peritoneal cavity with ice-cold serum free RPMI 1640 medium using 
a 22G needle. Fluid was centrifuged in a 15 mL conical centrifuge tube at 1200 rpm for 5 min 
at 4
o
C, and the pellet was resuspended in RPMI 1640 medium supplemented with 10% heat-
inactivated FCS, 15 mM HEPES buffer and 1% penicillin/streptomycin.  Cell lysis buffer was 
used for red blood cell lysis. Remaining cells were counted and checked for viability by the 
trypan blue dye exclusion method. Six million cells were cultured in a 70 mm petridish and 
incubated at 3h at 37
o
C for adherence. Non-adherent cells were removed by washing with 
serum-free RPMI 1640 medium.  
3.1 Cell migration/invasion assay 
Under sterile conditions 12-well transwell plates (Greiner bio one, Frickenhausen,Germany) 
with 8 "m pore size matrigel coated filters (BD-Matrigel) were used. Lower wells contained 
600 "l of islet supernatant, whereby the upper wells contained a final volume of 250 "l after 
the addition of cells. To begin the assay, 0.5#10
6
 cells in medium were added to the upper 
wells in the absence and presence of MMP inhibitors (5 mM captopril or 10 "M GM6001), 
and were allowed to migrate for 48 h at 37 °C in a 5% CO2 humidified atmosphere. After 
completion of migration cells were labeled with 450 "l of calcein AM (Sigma) that was added 
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to the lower chamber at 8 µM final concentration. Cells migrating to the underside of the filter 
were removed by using trypsin EDTA and detected using a fluorescence plate reader 
(Berthold Technologies-Mithras LB940, Bad Herrenalb, Germany). 
3.2 Transplantation experiment with captopril 
Captopril was dissolved in normal saline and injected subcutaneously for 7 days to mice (0.5 
mg/kg, n=10, C57 Bl/6) starting from the day of transplantation. Two thousand islet 
equivalents were transplanted into the portal vein of diabetic mice. Recipients were 
anesthesized with 2.5% avertine (Sigma). Fourteen days after transplantation grafted livers 
were retrieved for insulin extraction as described before (75). The transplants were 
homogenized mechanically and dissolved in acid ethanol and the supernatants were collected 
for quantification of insulin by ELISA (DRG Instruments, Marburg, Germany). 
3.3 Islet transplantation with MMP-2/9 inhibitor  
A hydrophobic cyclic peptide that acts as an inhibitor of MMP-2 and 9 (IC50 10 mM) was 
used to confirm results obtained from captopril treatment (MMP-2/9 inhibitor III, 
Calbiochem-Merck,NottinghamUK). Pig islets were transplanted to mice liver and MMP-2/9 
inhibitor was injected intravenously for 7 days into mice (15 mg/kg, n=4, C57 Bl/6) as 
described previously (75). Two thousand islet equivalents were transplanted into the portal 
vein of diabetic mice. Recipients were anesthesized with 2.5% avertine (Sigma).  
3.4 Statistics 
Student’s t-test and one-way Anova was applied for analysis of data. A value of p < 0.05 was 
considered significant (*p<0.05,  **p< 0.001, ***p<0.0001). 
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Chapter III - Results   
1. Gelatinase activity with normal islet and isolated islet 
2. Gelatinase activity increased in islet transplanted liver 
3. Immune cell migration in islet transplanted liver 
4. MMP-9 inhibition - Impact on leukocyte migration and islet function after transplantation 
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1. Gelatinase activity with normal islet and isolated islet  
1.1 Gelatinases are secreted by pancreatic beta cells  
Analysis of MMP-2 and MMP-9 secretion was performed in pig islet (Fig 1 A) and mouse 
islet (Fig. 1B) conditioned medium. MMP-2 (#62 kDa) and MMP-9 (pro form #92 and active 
#86 kDa) were present in cell-conditioned medium of islets. Secretion of MMP-9 was 
confirmed in islet-conditioned medium by zymography (I), an assay that is based on 
gelatinase degradation of the substrate gelatin. The presence of MMP-2 was confirmed using 
western blot (II). Western blot was performed most of the time for MMP-2 detection due to 
very faint band on Gelatine zymography. We also performed in situ zymography for 
analyzing gelatinase activity within islet in normal mouse pancreas and observed that islets 
are expressing gelatinase even in normal pancreas Fig. 2. 
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Fig.1 Expression of MMP-2 and MMP-9 in pig and mouse islets. Gelatin zymography (I) and 
western blot (II) revealed that MMP-2 (#62 kDa) and MMP-9 (#92 kDa, # 86) was expressed 
by pig (A) and mouse islets (B). 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 IL-1 beta and TNF alpha increased gelatinase secretion from isolated islet 
Islets were isolated from pig and checked for secretion of MMP-2 and MMP-9. Since 
pancreatic beta cells constitutively released limited amounts of MMP-2 and MMP-9 under 
quiescent conditions the influence of inflammatory cytokines in the context of transplantation 
on MMP-2 and MMMP-9 expression was carried out by western blotting and gel gelatin 
zymography. A dose dependent increase in MMP-9 activation was observed with IL1-beta 
II 
72 
55 
Fig 2 In situ zymography (ISZ) in wild 
type mouse pancreas. ISZ was 
performed for checking MMP activity 
in wild type mice pancreas sections. 
Fluorescent microscopy results 
depicting MMP activity (green) within 
islets. Nucleus was stained by DAPI 
(blue). 
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(Fig 3 A) and TNF- alpha (Fig 4A), whereas only TNF- alpha induced a dose dependent 
MMP-2 activation (Fig 8B). 
A 
 
                   
B 
 
 
IL1-beta 
Fig. 3 MMP9 secretion from IL1-beta treated islets. Primary islets were isolated from pig and 
were treated with IL1- beta (1, 10ng) for 24 hrs. Gelatinase secretion in the culture medium 
was detected by gelatin gel zymography. Dose dependent MMP-9 activation was observed 
with IL1- beta treatment after 24hrs but MMP-2 activity on gel gelatin zymography after IL1- 
72 
55 
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beta treatment was not clear (A) but MMP-2 expression was not significantly deferent (B). 
The blots shown are representative of at least three independent experiments performed. 
 
 
 A 
 
                 
B              
                        
 
                 TNF- alpha 
Fig. 4 TNF alpha stimulates MMP-9 and MMP-2 from pig islets. Conditioned medium were 
taken after 24 hrs treatments of different doses of TNF- alpha (1 ng, 10 ng) and analyzed by 
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gel zymography (A) and western blotting (B). Does dependence of TNF- alpha stimulated 
MMP-9 (A) and MMP-2 (B) was observed.  
 
2  Gelatinase activity increased in islet transplanted liver 
To verify gelatinase expression in normal and islet-transplanted liver, RT-PCR, in situ 
gelatine zymography and immunostaining were performed. RT-PCR showed higher 
expression of MMP-9 in transplanted as compared to control mice (Fig. 5A). Quantification 
of band intensity indicated significant increases in MMP-9 mRNA (Fig. 5B) in the 
transplanted group as compared to control, while MMP-2 mRNA levels did not change after 
transplantation (Fig. 5C). 
Analysis of gelatinase activity by in situ zymography provided information about the precise 
localization of MMP-2 and MMP-9 activity in liver sections by dye-quenched DQ-gelatin 
labeling using fluorescein isothiocyanate. The basal MMP activity was low in untreated 
animals (Fig. 6A), whereas in islet-transplanted liver it was increased (Fig. 6B). Next, we 
examined MMP-9 immunostaining within control (Fig. 6C) and islet-transplanted liver (Fig. 
6D) and found the same pattern. Hepatic MMP-9 activity increased in the vicinity of the 
transplanted islets (Fig. 6B,D), and was also observed within them (Fig. 7A,B) but as a rare 
event. We did not observe gelatinase activity in islet after transplantation as it was in normal 
pancreas (Fig. 6 B, D).  
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Fig. 5 MMP9 expression in transplanted liver. 
mRNA levels of MMP-2 and 9 were analyzed by RT-PCR in total RNA extracts from control 
liver (A, lanes 1,4) and islet-transplanted liver (A, lanes 2,3). The difference between MMP-9 
expressions in transplanted mice was significantly higher in comparison to control mice (B,*P 
< 0.05, n=3). MMP-2 mRNA level was not significantly different in control and islet-
transplanted liver (C, P >0.05, n=3). 
 
 
 
Fig. 6 Gelatinase activity in islet-transplanted liver.  
Control liver sections (A, C) and islet-transplanted liver sections (B, D) were analyzed by in 
situ zymography (ISZ) for gelatinase activity (A, B green) as well as stained with specific 
antibody for MMP-9 immunoreactivity (C, D green). The figures are representative of four 
independent experiments. (Magnification #200 inserts #400). Insulin (red) and DAPI (blue) 
was stained for localization of islet and nucleus, respectively.  
 
MMP-2 and MMP-9 activation in islet-transplanted liver was detected in association with 
platelets and thrombus-like material (Fig. 7C) as indicated by staining with an antibody 
against GpIIb/IIIa (Fig. 7D). Increased gelatinase action was also observed in proximity to 
CD11b cells (Fig. 7E,F), a prominent cell type that appears within liver tissue after islet 
transplantation 
 - 40 - 
 
Fig 7 Gelatinase activity associated with islet transplant. 
Following transplantation of islet grafts into liver for 4 h, in situ zymography (ISZ, green) for 
gelatinase activity (A) and immunostaining for MMP-9 (B, green) was performed, which 
showed increased gelatinase activity within a transplanted islet. In situ gelatin activity (C, 
green) was also seen next to thrombus material, which was confirmed by staining platelets 
aggregates (D, green) with GbIIb/IIIa antibody. Gelatinase activity (E-F, green) was costained 
with CD11b positive cells (red) in islet-transplanted liver. The figures are representative of 
three independent experiments. Magnification #400.  
 
3. Immune cell migration in islet transplanted liver 
3.1 F4/80 positive cell migration 
Islets were transplanted (Tx) in mice liver and after 30min, 4h and 24h liver was removed and 
frozen immediately. Cryosections were prepared and stained for F4/80 positive cells. More 
F4/80 positive cells migrated towards islet transplanted liver after 4h and 24h compared to 
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30min (Fig 8 B,C,A). Cells were count by using Image J Software and statistic analysis was 
done with GraphPad prism software, which showed significant difference in F4/80 cell 
migration in islet vicinity after transplantation (Fig 8 E). 
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Fig.8 F4/80 cell migration. Increased number of F4/80 positive cells were observed after 4h 
(B, *P<0.05) and 24h (C, **P<0.001) compared to 30min (A) in islet-transplanted liver. Red 
color is showing islets stained with insulin antibody. Nuclei were stained with DAPI (blue) 
(200# magnification). (D) Cells were counted by using Image J Software and statistic analysis 
(GraphPad prism software) was done for comparing control and transplanted liver F4/80 
positive cells. (E) Same method was used for counting F4/80 positive cell migration in 
vicinity of islet at different time point after transplantation. Color of islet and F4/80 cells were 
interchanged for creating a comparable color with other figures.  
 
3.2 CD11b positive cell migration 
Liver leukocytes cells were prepared after 4h of islets transplantation and stained with 
CD11b. FACS data showed 52% CD11b positive cells cells in islet-transplanted mice liver in 
comparison with 11% non-transplanted control liver (Fig 9).  
 
        A 
11% 
 - 43 - 
                        
B 
 
 
Fig.9 CD11b cell migration. FACS data showed more CD11b positive cells in islet-
transplanted mice liver compared to non-transplanted control mice. 
4. MMP-9 inhibition - Impact on leukocyte migration and islet function after 
transplantation 
We observed that pancreatic islets had gelatinase activity in normal pancreas. Yet, they were 
not able to produce the same amount after transplantation. On the other hand, there was 
increased gelatinase activity in liver after transplantation, which was associated with other 
cell type. Since MMP-9 secretion was increased in transplanted as compared to non-
transplanted liver, the role of MMP-9 after transplantation was investigated. CD11b cell 
migration was examined in two transplantation models using MMP-9 KO mice as recipients 
and captopril as gelatinase inhibitor. 
4.1 MMP-9 KO mice and migration of CD11b
 
positive cells 
To confirm the absence of MMP-9 activity in MMP-9 KO mice liver after islet transplantation 
substrate zymography was performed (Fig 10 I). Gel zymography is based on degradation of 
gelatin giving precise information about MMP-2 and MMP-9 activity with their pro and 
active forms. We did not observe activity of MMP-9 in MMP-9 KO islet- transplanted liver 
52% 
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though MMP-9 activity was present in wild type islet-transplanted liver. Since MMP-9 
secretion was inducible in the islet-transplanted liver but not in control liver, the role of 
MMP-9 after transplantation was further investigated by analyzing the distribution of CD11b-
positive (neutrophils and macrophages) cells using MMP-9 KO and respective control mice as 
recipients. It is known from previous studies that MMP-9 is actively involved in recruitment 
of CD11b-positive cells driving inflammatory processes such as in post-ischemic liver and 
neutrophil migration (77; 78). Thus, we examined the involvement of MMP-9 in migration of 
CD11b-positive cells to the pancreatic islet transplants.  
I 
                      
II 
 
 - 45 - 
Fig 10. MMP-9 in CD11b cell migration after islet transplantation. (I) Islets were transplanted 
in mice liver and gelatinase activity was compared in MMP-9KO and normal mice. (II) 
Cryosections from islet transplanted liver were prepared and stained for CD11b positive cells 
(green) in wild type transplanted, MMP-9 KO transplanted mice and non-transplanted control 
mice liver. (A,B) Sections from wild type mouse liver without islet transplantation showed 
few CD11b positive cells. (C, D) More CD11b positive cells migrated in wild type mouse 
liver with transplanted islets (red). (E, F) MMP-9 KO liver with transplanted islets (red) 
showed less CD11b positive cells. Nuclei were stained with DAPI (blue). Magnification 
200#. FACS data, which is placed next to respective immunostaining figures showed 67% 
CD11b cells in wild type transplanted mice compared to 45% in MMP-9 KO transplanted 
mice. 
 
Only very few leukocytes were observed in non-transplanted control liver (Fig. 10II,A-B). 
Their number was increased in sections of wild-type recipient mice with hepatic islet grafts 
(Fig. 10II,C-D) compared to MMP-9 KO recipients (Fig. 10II,E-F). These results were 
confirmed by FACS analysis of liver leukocyte cells, where we found 67% CD11b-positive 
cells in wild-type islet-transplanted liver as opposed to 45% in MMP-9 KO mice.  
4.2 Inhibition of gelatinase activity by captopril by direct inhibition not via angiotensin 
II  
Next we examined the effect of captopril on gelatinase inhibition. Islets were transplanted into 
C57Bl/6 mice liver in the absence or presence of captopril. Livers were removed after 4 h of 
transplantation and explored for gelatinase activity by substrate zymography (Fig. 11A). 
Increase in MMP-9 activity (pro#92KDa and active#86KDa) was observed in wild type islet 
transplanted liver, which was inhibited in captopril treated mice (Fig 11). 
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Fig 11. Zymography with and without captopril treatment. Islet-transplanted liver isolated 
from mice injected with captopril was used for gel gelatin zymography (A). Gelatinase 
activity was not present in control liver (A, lane 1; M = Marker) though it was increased 4 h 
after islet transplantation (A, lane 2) and was inhibited by captopril injection (A, lane 3). In 
situ gelatin zymography (B, green) was performed without (a) or with (b) addition of 
captopril in islet-transplanted liver sections. Captopril inhibited MMP activity (green) in islet 
(red) surrounding (b). Nucleus was stained with DAPI.  
 
There was no detectable MMP-2 activity in islet-transplanted liver. Captopril was used to 
inhibit gelatinase activity and its effect was confirmed by in situ zymography. Administration 
of 10 mM captopril completely abrogated enzymatic activity on tissue sections  (Fig. 11B). 
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As captopril can inhibit MMP either by direct Zn
2+
 inhibition or angiotensin II inhibition. We 
performed EMMPRIN immunostaining for dissecting captopril function, which is a 
downstream molecule of the angiotensin II system. From this experiment we observed 
complete lack of CD147 expression in islet-transplanted liver (Fig12). 
 
Fig 12.EMMPRIN staining in islet transplanted liver. Sections were stained with antibody 
against extracellular matrix metalloproteinase inducer (EMMPRIN, CD147, red), anti-insulin 
antibody (green) for islets and DAPI for nucleus. Mouse testis section (A) was used as 
positive control for antibody CD147. Control Liver section without islet transplantation (B) 
was also stained for CD147. Pig islets were transplanted into mice liver with (C) and without 
(D) captopril treatment. Four hours later islet-transplanted livers were retrieved and snap-
frozen in liquid nitrogen for further processing. While transplanted islets showed significant 
insulin staining, CD147 was expressed neither in beta cells nor other types of cells. 
 
4.3 Mouse macrophage invasion was inhibited by Captopril and GM6001 in vitro 
Macrophages are known to migrate towards transplanted islets (20). We observed that there 
was a significant increase in F4/80-positive cell migration towards islet grafts after 4 h and 24 
h after transplantation. To determine the specificity of captopril treatment, macrophage 
invasion was performed in vitro in the absence and presence of GM6001 (10 "M), a well-
known gelatinase inhibitor, and captopril (5 mM).  
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Fig 13. Murine peritoneal macrophages were allowed to migrate with or without MMP 
inhibitors . Numbers are expressed as the percentage of macrophage migrated towards islet-
conditioned medium without inhibitor. Macrophage migration was significantly inhibited by 
captopril in TNF- alpha ( **P< 0.001, n=3) and IL1- beta treated cell-conditioned medium ( 
**P<0.001, n=3). The effect was also significant when macrophages were treated with 
GM6001 ( *P<0.05, *P<0.05, B, n=3). 
 
To determine the specificity of captopril treatment, macrophage migration was measured in 
the absence or presence of the specific gelatinase inhibitor GM6001 (10 "M) and captopril (5 
mM). As shown in Fig. 13, significant inhibition of macrophage migration towards TNF-
alpha treated islet cell-conditioned medium occurred in the presence of captopril or GM6001 
(Fig. 13). A similar effect was observed when macrophages were subjected to IL1- beta 
treated islet cell-conditioned medium in the presence of captopril or GM6001.  
4.4   Neutrophil and macrophage migration after MMP-9 inhibition in vivo 
The influence of MMP-9 inhibition on in vivo macrophage and neutrophil migration was 
studied. Following islet transplantation, immunostaining for CD11b and Ly6G was performed 
(Fig. 14). CD11b and Ly6G-positive cell numbers were increased in wild type transplanted 
mice as opposed to those animals treated with captopril or MMP-2/9 inhibitor and in 
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transplanted MMP-9KO mice, altogether demonstrating that this effect was mediated mainly 
by inhibition of MMP-9. 
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Fig. 14 MMP-9 inhibition and reduction of leukocyte migration to the transplanted islets.  
Leukocyte migration was quantitated in islet-transplanted liver sections with and without in 
vivo MMP-9 inhibition. CD11b (Mac-1) staining revealed significant inhibition of CD11b 
positive cell migration towards islet-transplanted liver in captopril or MMP-2/9 inhibitor- 
treated and MMP-9 KO mice compared to wild type islet-transplanted mice (WT-Tx) (A, 
**P<0.001, n=3 mice). Number of Ly-6G positive cells was also reduced in captopril, MMP-
2/9 inhibitor treated and MMP-9 KO animals alike compared to WT-Tx. (B, **P<0.001, n=3, 
three fields per section).  
 
4.5 Islet transplantation in vivo  
When pig islets were transplanted to C57Bl/6 recipients with streptozotocin-induced diabetes, 
blood glucose was initially normalized, but diabetes recurred within five days as expected.  
 
Fig. 15 Captopril and graft function. 
Captopril was injected subcutaneously for 7 days to mice transplanted with pig islets (n=10 in 
each group). Mean blood glucose levels in the captopril-treated group (A, black triangle) were 
lower then control group (A, black squares). Statistic analysis showed significant difference in 
mean blood glucose value (B, *P<0.05). Insulin content of liver grafts retrieved from 
recipients after 14 days of transplantation in the captopril-treated group was increased 
compared to the untreated liver grafts (C, ***P<0.0001). Log-rank analysis of the graft 
survival curve determined from daily blood glucose levels showed significant difference (D, 
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***P<0.0001) of groups of transplanted mice treated with captopril (black triangle) or with 
solvent (black squares). The day of graft loss was defined as the last one of successive levels 
of > 16.7 mmol/l glucose.  
 
The rejection was delayed in the captopril-treated group as compared to the control group and 
mean blood glucose levels in the captopril-treated group were lower (Fig. 15A, B). 
At the end of the experiment, insulin contents of the grafts retrieved from recipients treated 
with captopril were significantly increased as compared to controls (Fig. 15C). Log-rank 
analysis of the graft survival curve revealed that treatment with captopril significantly 
extended survival times as compared to controls (Fig. 15D). These data indicated that 
gelatinase inhibition is beneficial for early islet engraftment. 
Improved early islet graft function after captopril treatment was compared with the specific 
gelatinase inhibitor MMP-2/MMP-9 III. We observed decreased blood glucose level in MMP-
2/9 inhibitor-treated mice compared to islet-transplanted mice without MMP inhibitor 
treatment. The transplantation experiments confirm that inhibition of gelatinases is an 
effective treatment in early islet transplantation (Fig. 16A,B). 
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Fig. 16 MMP-9 inhibitor peptide and graft function. 
MMP2/9 inhibitor (15 mg/kg) was injected intravenously for 7 days to mice transplanted with 
pig islets (n=4 in each group). Mean blood glucose levels in the group treated with the 
inhibitor (A, black triangles) were lower compared to the control group (A, black squares). 
Statistic analysis showed a significant difference in mean blood glucose value (B, *P<0.05). 
The day of graft loss was defined as the last one of successive levels of > 16.7 mmol/l 
glucose.  
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Chapter IV 
1.Gelatinase secretion from islet in normal and inflammatory conditions 
2.Increased gelatinase activity in islet transplanted liver 
3.Immune cell migration increased after early islet transplantation 
4.Gelatinase inhibition decreased immune cell migration and increased islet graft survival 
5. Gelatinase inhibitors and their impact on clinical islet transplantation 
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Discussion 
In particular, gelatinases have long been known to enhance inflammatory cell migration or to 
generate the biological active forms of cytokines (2,3,35). Islet infusion into the portal vein 
was assumed to induce protease activity in the context of an instant inflammatory or 
procoagulant response triggered by tissue factor or blood constituents (56) and may 
potentially be amplified by drainage of endotoxins from the intestine (79). As early islet graft 
loss is associated with immune mediated destruction, we hypothesized that gelatinase 
inhibition can inhibit immune cell migration and can increase graft survival. 
1. Gelatinase secretion from islet in normal and inflammatory conditions 
Immune cells infiltrate to liver after islet transplantation and increase proinflammatory 
cytokines inside liver (80). So firstly, we examined MMP secretion by pancreatic islet and 
found that MMP-2 and 9 secretions are low, but under tight control of cytokines, such as IL1- 
beta or TNF- alpha they increased. Though it is well known that MMP-2 is a constitutively 
regulated protease (81) we also observed that isolated islets are secreting MMP-9 without any 
stimulation. However, it is already shown that islets are expressing MMP in acute pancreatitis 
and in type 1 diabetes (71-73). Further we checked gelatinase activity in pancreatic islet 
inside normal pancreas and found high gelatinase activity within islet, which suggest that 
MMPs are normally expressed in islets. On the other hand we found very little or no 
gelatinase activity within transplanted islet, as after transplantation gelatinase activity is 
mostly associated with other cells in islet surrounding.  
We hypothesise from these observations that MMPs are important for islet normal activity, 
which includes cell cycle and insulin secretion. After transplantation reduced gelatinase 
activity may influence islet survival though the exact function is not understood. 
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    A      Wild Type Pancreas   B Islet Transplanted Liver 
 
 
 
 
      
C   Islet Transplanted Liver 
 
 
 
 
 
Fig.1 Gelatinase activity decreased after islet transplantation but increased in islet vicinity. 
Wild-type pancreas section with gelatinase (green) activity within islet (A). Islet (red-insulin 
staining) transplanted liver showed gelatinase activity (green) in the surroundings of grafted 
islet (B). MMP-9 was also stained (green) with antibody. Nucleus was stained with DAPI 
(blue). 
2. Increased gelatinase activity in islet transplanted liver 
Gelatinase activity in association with transplanted islets was significant in surrounding tissue 
but was minor within islet grafts. We observed a preferential increase of its activity in non-
endocrine cells, such as in neutrophils, platelets and hepatocytes. Accordingly, no 
morphological reorganization of transplanted islets was observed, such as aggregation or re-
arrangement of endocrine cells. In addition elevated levels of MMP-9 mRNA and protein 
were found in the recipient liver, while MMP-2 mRNA expression was essentially the same in 
control or transplanted mice liver and not detectable at the protein level. These data indicate 
that increased MMP-9 expression and activity provides a likely candidate responsible for 
early islet graft loss.  
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 It has been shown previously that MMP-9 plays an important role in revascularization of 
transplanted pancreatic islets following culture with stimulators of angiogenesis. Despite 
improved revascularization, control mice showed better response to glucose challenge than 
MMP-9 treated mice (82). As Gelatinase B is diabetogenic in acute and chronic pancreatitis 
by cleaving insulin (71), this could make mice less responsive for glucose challenge after 
MMP-9 treatment of islet.  
3. Gelatinase and immune cell migration after early islet transplantation 
Both neutrophils and macrophages express and secret gelatinases (2,3). Previous studies have 
shown that such cells contribute to the first line of rejection (50; 51). Neutrophils are a key 
component of the inflammatory response. They can generate chemotactic signals and thereby 
attract dendritic cells and macrophages (83; 84). Since neutrophil chemotaxis has been 
reported to occur in islet grafts, the influence of pharmaceutical MMP inhibition on migration 
of Ly6G-positive cells towards transplanted islets has been investigated. Previous reports 
showed that neutrophils play a major role in early graft loss by increasing local interferon-
gamma production (51). We also confirmed that CD11b and Ly6G-positive cells were the 
main mediators of the instant inflammatory reaction following islet transplantation. Moreover, 
by therapeutically targeting these cells with MMP inhibitors the functional damage to the 
graft observed during the very first hours was reduced. No significant enhancement of F4/80-
positive cells was noted in complete liver section 24 h after islet transplantation as compared 
to non-transplanted liver sections. We observed a slight increase in the number of F4/80 
positive cells in surroundings of transplanted islets at 4 h and 24 h as opposed to 30 minutes 
post transplantation. However, within 4 h following transplantation, CD11b accumulation was 
enhanced in islet-transplanted liver.  
Islet transplantation to liver increases proinflammatory cytokines (80). Similarly, it has been 
observed that inflammatory cytokines can increase MMP-9 secretion from different cell types 
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such as –macrophages, neutrophils and hepatocytes (85-87) and can aggravate inflammatory 
reactions. 
4. Gelatinase inhibition decreased immune cell migration and increased islet graft 
survival 
The mechanisms for in vivo activation of secreted MMPs in transplantation are not well 
understood. Therefore, we decided to investigate their role in a recently acute in vivo 
inflammatory model of pancreatic islet transplantation. We assumed that a large number of 
mediators will be released following transplantation and they will interact with each other to 
make the picture even more complicated. In such a complex situation it was our aim to 
identify master mediators of the IBMIR.  
 
 
 
 
 
 
 
 
Fig.2 Influence of gelatinase on islet transplantation. Gelatinases are increased in islet vicinity 
after islet transplantation and they increased immune cell migration towards transplanted islet. 
Inhibition of gelatinase can inhibit immune cell migration and thereby can influence islet graft 
survival. 
 
We employed two approaches, namely transplantation into MMP-9 knockout mice and 
application of the MMP inhibitors captopril and MMP-2/9 inhibitor III to study transplant 
function. In the first experiment, accumulation of CD11b-positive cells in the islet-
transplanted liver was reduced, indicating that MMP-9 supports early islet graft loss by 
increasing immune cell infiltration to the site of transplantation. From these data we conclude 
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that the recipient tissue devoid of MMP-9 is apparently protected against inflammatory cell 
infiltration towards grafted islets, and thus, graft survival is increased.  
In the second approach, in vitro and in vivo functional studies were performed with captopril 
and MMP-2/9 inhibitor III as prominent gelatinase inhibitors. Captopril forms complexes with 
the catalytically functional zinc ion present at the active site of angiotensin-converting 
enzyme (ACE) and gelatinase (88-91). To dissect which of the two zinc-dependent proteases 
ACE or gelatinase are more prominent in pancreatic islet transplantation we compared 
EMMPRIN/CD147 (extracellular matrix metalloproteinase inducer) immunostaining in islet 
transplanted sections, as EMPRIN/CD147 is downstream of angiotensin II pathway. It is 
known that angiotensin II stimulates EMMPRIN (extracellular matrix metalloproteinase 
inducer) that leads to upregulation of MMP (92). In confirmation, we were not able to detect 
significant expression in liver after islet transplantation, not to mention down-regulation by 
captopril.  
Captopril amplified the glucose-lowering function of transplanted islets more effectively than 
losartan indicating that metalloproteases are activated minutes after intraportal islet 
transplantation by mechanisms other than the angiotensin receptor. Not only was the drug 
able to inhibit macrophage migration/invasion towards islet supernatant in vitro, similar to the 
action of the MMP inhibitor GM6001, but also captopril treatment was found to increase 
insulin content and reduce blood glucose levels when compared to untreated mice. MMP-2/9 
inhibitor III also improved blood glucose level in transplanted diabetic mice and in addition, 
reduced neutrophil and macrophage accumulation in islet-transplanted liver to the same extent 
as found in captopril treated or MMP-9 KO recipient mice.  Both captopril and MMP-2/9 
inhibitor III can reduce MMP activity, but as only MMP-9 protein level was increased after 
islet transplantation to liver, it was assumed that the observed effect was predominantly 
specific for MMP-9. Together, these data demonstrate that MMP-9 inhibition has an 
important positive influence on islet graft survival. Thus, inhibition of gelatinase B activity in 
 - 59 - 
early pancreatic islet grafts serves as a protective treatment for the reduction of leukocyte 
infiltration and for the restoration of inflammation and graft function. 
5. Gelatinase inhibitors and their impact on clinical islet transplantation 
Till now it has not been convincingly shown that MMP inhibition has an effect on the 
outcome of islet transplantation. Our results demonstrate that reduction of MMP activity will 
prevent instant inflammatory reactions during the first hours and days following intraportal 
islet transplantation. This will result in a long-term benefit for the engrafted islets because it is 
known that up to half of the total of transplanted islet cells will suffer severe damage from 
instantaneous attack of neutrophils. Therapies directed at neutrophils and other components of 
the innate immune system, such as complement and proteins of the coagulation cascade are 
lacking in human islet transplantation programs at the moment. MMP-inhibiting drugs could 
be combined with anti-CD3 antibodies in clinical regimens to antagonize both neutrophils and 
T-lymphocytes. 
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